Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary New REGENERATE Interim Analysis Data Presented at The Liver Meeting® Report OCA Improved Multiple Noninvasive Markers of Liver Fibrosis in Patients with NASH
Treatment with OCA resulted in early and sustained improvements of commercially available noninvasive biomarker and imaging assessments of fibrosis Additional patient-reported outcomes data demonstrate that pruritus in patients treated with OCA 25 mg did not have an impact on measures of quality of
View HTML
Toggle Summary Intercept Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update
Worldwide Ocaliva net sales of $61.5 million in the third quarter of 2019 representing 32% growth versus the prior year quarter; increasing full year 2019 worldwide Ocaliva net sales guidance range to between $245 million and $250 million U.S. NDA for NASH submitted; EU MAA submission for NASH
View HTML
Toggle Summary Intercept to Announce Third Quarter 2019 Financial Results on November 5, 2019
NEW YORK , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2019 financial results prior
View HTML
Toggle Summary Intercept Announces New NASH and PBC Data to be Presented at The Liver Meeting® 2019
New analyses from Phase 3 REGENERATE study evaluating the effects of OCA on non-invasive liver fibrosis tests and NASH patient-reported outcomes Five-year analysis of long-term Ocaliva ® treatment in patients with PBC selected for inclusion in ‘Best of the Liver Meeting’ abstracts NEW YORK , Oct.
View HTML
Toggle Summary Intercept Submits New Drug Application to the U.S. FDA for Obeticholic Acid in Patients with Fibrosis Due to NASH
NDA supported by positive interim analysis results from REGENERATE Phase 3 study demonstrating OCA’s improvement of liver fibrosis without worsening of NASH   NEW YORK , Sept. 27, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the
View HTML
Toggle Summary Intercept to Present at Upcoming Investor Conference in October
NEW YORK , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the
View HTML
Toggle Summary Intercept Launches NASHTRUTH.com, an Online Educational Resource for People with Advanced Fibrosis Due to NASH
New NASH survey available on NASHTRUTH.com reveals that 6 out of 10 NASH patients say there is not enough information about the disease available to them   NASHTRUTH.com provides people living with NASH with resources to start a more productive dialogue with their healthcare providers about their
View HTML
Toggle Summary Intercept Appoints Lisa DeFrancesco as Vice President, Investor Relations
NEW YORK , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Lisa DeFrancesco as Vice
View HTML
Toggle Summary Intercept to Present at Upcoming Investor Conferences in September
NEW YORK , Aug. 23, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be participating at the
View HTML
Toggle Summary Intercept Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update
Company delivers strongest quarter to date with worldwide Ocaliva ® net sales of $65.9 million in the second quarter of 2019, representing 53% growth versus the prior year quarter U.S. NDA filing for NASH on track for third quarter of 2019; EU MAA filing for NASH projected for fourth quarter of
View HTML